Company Description (as filed with the SEC)
Marshall Edwards, Inc. (“MEI”) including its wholly-owned subsidiary Marshall Edwards Pty Ltd (“MEPL”) (together, the “Group” or the “Company”) is a development stage company incorporated in December 2000 as a wholly-owned subsidiary of Novogen Limited. Our shares of common stock are listed on the NASDAQ Global Market under the symbol “MSHL”. As of the date of this Annual Report on Form 10-K Novogen owns approximately 71.3% of the outstanding shares of our common stock. Our business purpose is the development and commercialization of drugs for the treatment of cancer. We are presently engaged in the clinical development and commercialization of our drug candidates triphendiol, NV-143 and NV-128 which we have licensed from a subsidiary of Novogen Limited (Novogen Limited and/or its subsidiaries are referred to herein as “Novogen”). ... More ...